drugset / Trial / NCT02176551

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

NCT02176551 ↗

Phase 3 Withdrawn Fougera Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.

Timeline

Start
2012-06
Primary completion
2013-05
Completion
2013-05

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Product 0405 Unknown — Topical

Indications